Sunmax Biotechnology Co., Ltd.
4728.TWO
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.57B
Close$
Share Statistics
| Market cap | $21.57 Billion |
|---|---|
| Enterprise Value | $21.29 Billion |
| Dividend Yield | $23.70 (3.06%) |
| Earnings per Share | $13.33 |
| Beta | -0.13 |
| Outstanding Shares | 54,463,000 |
Return
| Return on Equity | 56.71% |
|---|---|
| Return on Assets | 40.55% |
| Return on Invested Capital | 78.43% |
Valuation & Multiples
| P/E Ratio | 26.58 |
|---|---|
| PEG | 47.05 |
| Price to Sales | 9.9 |
| Price to Book Ratio | 15.23 |
| Enterprise Value to Revenue | 9.7 |
| Enterprise Value to EBIT | 17 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sunmax Biotechnology Co., Ltd.
30 employees
CEO: Ming Yi Lin Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across T...